Search | Clinical Trials Finder

Conditions: Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions: gemcitabine hydrochloride, paclitaxel, tipifarnib, radiation therapy; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lung Cancer, Breast Cancer, Gastrointestinal, Lymphomatous Malignancies
Interventions: Not listed
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: F-Var3 PET/CT, Blood draw; Diagnostic Test · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Glioma
Interventions: Temozolomide; Drug
Lead sponsor: Kentuckiana Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Prostate Cancer
Interventions: Saw Palmetto, soybean oil soft gel; Drug
Lead sponsor: Michigan State University; Other
Eligibility: 21 Years and older · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 6
States / cities: Jackson, Michigan • Lansing, Michigan • Mount Clemens, Michigan + 2 more

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Avelumab, Chemoradiation; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 697 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 139
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 91 more

Conditions: Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Superior Sulcus Lung Carcinoma
Interventions: Atezolizumab, Biopsy, Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Etoposide, External Beam Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pemetrexed, Positron Emission Tomography, Therapeutic Conventional Surgery; Biological · Procedure · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 46
States / cities: Jonesboro, Arkansas • Tampa, Florida • Boise, Idaho + 41 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Proton beam radiation therapy (PBT), Paclitaxel, Carboplatin; Radiation · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Basal Cell Carcinoma of the Lip, Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage III Lymphoepithelioma of the Nasopharynx, Stage III Lymphoepithelioma of the Oropharynx, Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: hydroxyurea, fluorouracil, bevacizumab, radiation therapy, filgrastim, laboratory biomarker analysis; Drug · Biological · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy; Radiation · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: Houston, Texas • League City, Texas • Sugar Land, Texas

Conditions: Cancer of Head and Neck
Interventions: concurrent chemo + IGRT, neoadjuvant chemo + IGRT; Radiation
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain Metastases
Interventions: whole brain radiation therapy; Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Leukemia, Lymphoma, Oral Complications
Interventions: filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, peripheral blood stem cell transplantation, quality-of-life assessment, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Central Nervous System Nongerminomatous Germ Cell Tumor, Childhood Germinoma
Interventions: 3-Dimensional Conformal Radiation Therapy, Carboplatin, Etoposide, Ifosfamide, Intensity-Modulated Radiation Therapy; Radiation · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 149
States / cities: Birmingham, Alabama • Phoenix, Arizona • Downey, California + 115 more

Conditions: Lung Cancer
Interventions: Prophylactic cranial irradiation, 2.5 Gy fx, Prophylactic cranial irradiation, 2.0 Gy fx, Prophylactic cranial irradiation, 1.5 Gy fx; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: Up to 120 Years
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 217
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 160 more

Conditions: Pancreatic Cancer
Interventions: Stereotactic Body Radiation Therapy, Preoperative Fractionated Radiation Therapy and Chemotherapy; Radiation
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Lung Cancer
Interventions: filgrastim, pegfilgrastim, cisplatin, docetaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 76
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Concord, California + 64 more

Conditions: Prostate Cancer
Interventions: PBRT, PLNRT, AA, LHRH agonist; Radiation · Drug
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 1,792 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 444
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 316 more

Conditions: Glioblastoma Multiforme, Astrocytoma, Grade III
Interventions: ADV/HSV-tk (gene therapy); Drug
Lead sponsor: David Baskin MD; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Breast Carcinoma
Interventions: Counseling, Educational Intervention, Questionnaire; Other · Behavioral
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Recurrent Glioblastoma Multiforme
Interventions: 131-I-chTNT-1/B MAB; Drug
Lead sponsor: Peregrine Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 4
States / cities: Phoenix, Arizona • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more

Conditions: Oncology, Spine Metastases
Interventions: Radiation Therapy, Radiofrequency Ablation (RFA); Radiation
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer
Interventions: 5 Fraction Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 2
States / cities: Birmingham, Alabama

Conditions: Prostate Cancer, Radiation Toxicity, Urinary Complication
Interventions: Lisinopril Tablets; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Rochester, New York

Search by objective public record fields.

Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer

DIBH Proton Planning

Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer

A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma

Saw Palmetto: Symptom Management for Men During Radiation Therapy

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer

Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

Adaptive Radiation Therapy for Head & Neck Cancer Patients

Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer

Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer

Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study

Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme

Radiation Therapy Alone Versus Radiation Therapy Plus Radiofrequency Ablation (RFA)/Vertebral Augmentation

RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer